As of close of business last night, Catalyst Pharmaceuticals Inc’s stock clocked out at $15.26, down -3.05% from its previous closing price of $15.74. In other words, the price has decreased by -$0.48 from its previous closing price. On the day, 1095287 shares were traded.
Ratios:
To gain a deeper understanding of CPRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.68 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 14, 2024, initiated with a Buy rating and assigned the stock a target price of $27.
On March 07, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $23.
On December 21, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $30.Oppenheimer initiated its Outperform rating on December 21, 2023, with a $30 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 27 ’24 when Elsbernd Brian sold 25,000 shares for $16.44 per share. The transaction valued at 411,000 led to the insider holds 124,433 shares of the business.
Harper Molly sold 14,000 shares of CPRX for $201,420 on Dec 15 ’23. The Director now owns 0 shares after completing the transaction at $14.39 per share. On Dec 12 ’23, another insider, Tierney David S, who serves as the Director of the company, sold 50,000 shares for $13.32 each. As a result, the insider received 666,250 and left with 333,541 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CPRX now has a Market Capitalization of 1.80B and an Enterprise Value of 1.66B. As of this moment, Catalyst’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.05, and their Forward P/E ratio for the next fiscal year is 9.56. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.52 while its Price-to-Book (P/B) ratio in mrq is 4.21. Its current Enterprise Value per Revenue stands at 4.18 whereas that against EBITDA is 13.91.
Stock Price History:
Over the past 52 weeks, CPRX has reached a high of $18.22, while it has fallen to a 52-week low of $11.09. The 50-Day Moving Average of the stock is 15.03, while the 200-Day Moving Average is calculated to be 14.06.
Shares Statistics:
It appears that CPRX traded 1.51M shares on average per day over the past three months and 1.15M shares per day over the past ten days. A total of 107.12M shares are outstanding, with a floating share count of 99.87M. Insiders hold about 15.27% of the company’s shares, while institutions hold 64.92% stake in the company. Shares short for CPRX as of Mar 15, 2024 were 5.83M with a Short Ratio of 3.86, compared to 5.67M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.94% and a Short% of Float of 6.10%.
Earnings Estimates
As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.24 for the current quarter, with a high estimate of $0.34 and a low estimate of $0.14, while EPS last year was $0.26. The consensus estimate for the next quarter is $0.3, with high estimates of $0.43 and low estimates of $0.2.
Analysts are recommending an EPS of between $1.5 and $0.85 for the fiscal current year, implying an average EPS of $1.16. EPS for the following year is $1.53, with 6 analysts recommending between $1.76 and $1.25.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $99.38M. It ranges from a high estimate of $107.32M to a low estimate of $91.4M. As of the current estimate, Catalyst Pharmaceuticals Inc’s year-ago sales were $85.37M, an estimated increase of 16.40% from the year-ago figure.
A total of 7 analysts have provided revenue estimates for CPRX’s current fiscal year. The highest revenue estimate was $477.91M, while the lowest revenue estimate was $455.47M, resulting in an average revenue estimate of $463.66M. In the same quarter a year ago, actual revenue was $398.2M, up 16.40% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $552.97M in the next fiscal year. The high estimate is $604.57M and the low estimate is $517.97M. The average revenue growth estimate for next year is up 19.30% from the average revenue estimate for this year.
